Patient and treatment characteristics
| Characteristic . | . |
|---|---|
| Total no. patients | 64 |
| Median age at transplantation, y (range) | 52 (17-72) |
| Sex, female/male, (%) | 24/40 (37.5/62.5) |
| Median time to transplantation, y (range) | 2.6 (0.2-18.1) |
| Prior treatments, % | |
| Median no. (range) | 3 (1-11) |
| Tyrosine kinase inhibitors | 9 (14.1) |
| Prior auto-SCT | 3 (4.7) |
| Prior allo-SCT | 7 (10.9) |
| Disease status at transplantation, % | |
| Chronic phase 1 | 13 (20.3) |
| Chronic phase 2 | 17 (26.6) |
| Accelerated phase | 29 (45.3) |
| Blast phase | 5 (7.8) |
| Preparative regimen, % | |
| FM 140 | 15 (23.4) |
| FAM 140 | 7 (10.9) |
| FM 180 | 30 (46.8) |
| FAI | 12 (18.8) |
| GVHD prophylaxis, % | |
| Tacrolimus/methotrexate | 58 (90.6) |
| Cyclosporine with and without steroids | 6 (9.4) |
| Characteristic . | . |
|---|---|
| Total no. patients | 64 |
| Median age at transplantation, y (range) | 52 (17-72) |
| Sex, female/male, (%) | 24/40 (37.5/62.5) |
| Median time to transplantation, y (range) | 2.6 (0.2-18.1) |
| Prior treatments, % | |
| Median no. (range) | 3 (1-11) |
| Tyrosine kinase inhibitors | 9 (14.1) |
| Prior auto-SCT | 3 (4.7) |
| Prior allo-SCT | 7 (10.9) |
| Disease status at transplantation, % | |
| Chronic phase 1 | 13 (20.3) |
| Chronic phase 2 | 17 (26.6) |
| Accelerated phase | 29 (45.3) |
| Blast phase | 5 (7.8) |
| Preparative regimen, % | |
| FM 140 | 15 (23.4) |
| FAM 140 | 7 (10.9) |
| FM 180 | 30 (46.8) |
| FAI | 12 (18.8) |
| GVHD prophylaxis, % | |
| Tacrolimus/methotrexate | 58 (90.6) |
| Cyclosporine with and without steroids | 6 (9.4) |
Auto-SCT indicates autologous stem-cell transplantation; allo-SCT, allogeneic SCT; FM, fludarabine and melphalan; FAM, fludarabine, cytarabine and melphalan; and FAI, fludarabine, cytarabine and idarubicin.